Black Diamond’s Unique Approach

Utilizing our proprietary MAP platform, we are developing a pipeline of orally available, potent, and selective small molecule kinase inhibitors that target a range of driver mutations in cancer.

The Company’s first two disclosed programs are targeting groups of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) allosteric mutants. We are also progressing our early stage pipeline programs targeting groups of allosteric mutations in kinases relevant to cancer and/or rare genetic diseases that we have developed utilizing our MAP platform.

MAP Analysis of the Oncogene Mutational Landscape Generates
a Pipeline of Drug Discovery and Development Programs